Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date [Corrigendum]

Abstract

Sawalha Y, Bond DA, Alinari L. Onco Targets Ther. 2020;13:6573—6581. The authors have advised that there is an error in Table 2 on page 6579. The values “37% (0%)” in the first row for the Ibrutinib column should read “10% (0%)”. The authors apologize for this error and advise it does not affect the conclusions of the paper. Read the original article

Keywords

• btk
• zanubrutinib
• ibrutinib
• acalabrutinib